REGISTER RECORD · clinicaltrials.gov
NCT03746522
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
AS THE REGISTER RECORDS IT
Status and dates
| Status as listed | COMPLETED: completed |
|---|---|
| Register last updated | 2023-12-01 |
| Retrieved by this site | 2026-10-03 |
| Source | https://clinicaltrials.gov/study/NCT03746522 |
What this record shows
This entry describes research activity. It is not a statement about market authorisation, and it is not regulatory, legal or medical advice: a trial being listed, completed or halted says nothing about whether a substance may be sold or used anywhere. Status wording is reproduced as the register writes it and is never mapped onto a simpler vocabulary.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.